Vancomycin Monitoring in Children Using Bayesian Estimation

Background: Optimal monitoring of vancomycin in children needs evaluation using the exposure target with area under the curve (AUC) of the serum concentrations versus time over 24 hours. Our study objectives were to: (1) compare the accuracy and precision of vancomycin AUC estimations using 2 sampling strategies—1 serum concentration sample (1S, near trough) versus 2 samples (2S, near peak and trough) against the rich sample (RS) method; and (2) determine the performance of these strategies in predicting future AUC against an internal validation sample (VS). Methods: This was a retrospective cohort study using population-based pharmacokinetic modeling with Bayesian post hoc individual estimations in nonlinear mixed effects modeling (version 7.2). Pediatric subjects 3 months–21 years of age who received vancomycin ≥48 hours and had more than 3 drug samples within the first ⩽96 hours of therapy were enrolled. Outcome measures were the accuracy, precision, and internal predictive performance of AUC estimations using 2 monitoring strategies (ie, 1S versus 2S) against the RS (which was derived from modeling all serum vancomycin concentrations obtained anytime during therapy) and VS (from serum concentrations obtained after 96 hours of therapy). Results: Analysis included 138 subjects with 712 vancomycin serum concentrations. Median age was 6.1 (interquartile range, 2.2–12.2) years, weight 22 (13–38) kg, and baseline serum creatinine 0.37 (0.30–0.50) mg/dL. Both accuracy and precision were improved with the 2S, compared with 1S, for AUC estimations (−2.0% versus −7.6% and 10.3% versus 12.8%, respectively) against the RS. Improved accuracy and precision were also observed for 2S when evaluated against VS in predicting future AUC. Conclusions: Compared with 1S, the 2S sampling strategy for vancomycin monitoring improved accuracy and precision in estimating and predicting future AUC. Evaluating 2 drug concentrations in children may be prudent to ensure adequate drug exposure.

[1]  Roger W. Jelliffe,et al.  Are Vancomycin Trough Concentrations Adequate for Optimal Dosing? , 2013, Antimicrobial Agents and Chemotherapy.

[2]  B. Guglielmo,et al.  Desired Vancomycin Trough Serum Concentration for Treating Invasive Methicillin-resistant Staphylococcal Infections , 2013, The Pediatric infectious disease journal.

[3]  A. Raszynski,et al.  Acute Kidney Injury During Vancomycin Therapy in Critically Ill Children , 2013, Pharmacotherapy.

[4]  E. Capparelli,et al.  Improved Vancomycin Dosing in Children Using Area Under the Curve Exposure , 2013, The Pediatric infectious disease journal.

[5]  J. Cies,et al.  Nephrotoxicity in Patients with Vancomycin Trough Concentrations of 15–20 μg/ml in a Pediatric Intensive Care Unit , 2013, Pharmacotherapy.

[6]  B. Moffett,et al.  Analysis of Vancomycin Therapeutic Drug Monitoring Trends at Pediatric Hospitals , 2013, The Pediatric infectious disease journal.

[7]  J. Carapetis,et al.  Trough Concentrations of Vancomycin: Adult Therapeutic Targets Are Not Appropriate for Children , 2012, The Pediatric infectious disease journal.

[8]  Yuhki Sato,et al.  Is Peak Concentration Needed in Therapeutic Drug Monitoring of Vancomycin? A Pharmacokinetic-Pharmacodynamic Analysis in Patients with Methicillin-Resistant Staphylococcus aureus Pneumonia , 2012, Chemotherapy.

[9]  Jana Shaw,et al.  Inappropriate vancomycin therapeutic drug monitoring in hospitalized pediatric patients increases pediatric trauma and hospital costs. , 2012, The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG.

[10]  B. Meibohm,et al.  Creatinine‐Based Vancomycin Dosing Regimens in Neonates: There Is More to Consider Than the Variation in Drug Assay , 2012, Pharmacotherapy.

[11]  Lisa Tang,et al.  Evaluation of Vancomycin Dosing Regimens in Preterm and Term Neonates Using Monte Carlo Simulations , 2012, Pharmacotherapy.

[12]  D. Paterson,et al.  The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  R. Kullar,et al.  Effects of Targeting Higher Vancomycin Trough Levels on Clinical Outcomes and Costs in a Matched Patient Cohort , 2012, Pharmacotherapy.

[14]  G. Drusano,et al.  Vancomycin: we can't get there from here. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  M. Jahng,et al.  Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children. , 2011, The Journal of pediatrics.

[16]  Sara E Cosgrove,et al.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  M. H. Ensom,et al.  Limited Sampling Strategies for Predicting Area Under the Concentration-Time Curve of Mycophenolic Acid in Islet Transplant Recipients , 2010, The Annals of pharmacotherapy.

[18]  D. Levine,et al.  Therapeutic Monitoring of Vancomycin in Adults , 2009, Pharmacotherapy.

[19]  L. Benet,et al.  Current Recommended Dosing of Vancomycin for Children With Invasive Methicillin-Resistant Staphylococcus aureus Infections Is Inadequate , 2009, The Pediatric infectious disease journal.

[20]  A. Wong-Beringer,et al.  High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. , 2006, Archives of internal medicine.

[21]  Mary H. H. Ensom,et al.  Beyond Cyclosporine: A Systematic Review of Limited Sampling Strategies for Other Immunosuppressants , 2006, Therapeutic drug monitoring.

[22]  D. Greenblatt,et al.  Limited Sampling Strategy to Predict AUC of the CYP3A Phenotyping Probe Midazolam in Adults: Application to Various Assay Techniques , 2002, Journal of clinical pharmacology.

[23]  M. Barclay,et al.  Experience of once-daily aminoglycoside dosing using a target area under the concentration-time curve. , 1995, Australian and New Zealand journal of medicine.

[24]  M. Wysocki,et al.  Why monitor peak vancomycin concentrations? , 1995, The Lancet.

[25]  S. Boike,et al.  Monitoring Vancomycin Therapy , 1986, Drug intelligence & clinical pharmacy.

[26]  R. Jelliffe,et al.  Title: Are vancomycin troughs adequate for optimal dosing? , 2013 .

[27]  Sara E Cosgrove,et al.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  D. Levine,et al.  Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. , 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[29]  P. Marquet,et al.  Limited Sampling Models and Bayesian Estimation for Mycophenolic Acid Area under the Curve Prediction in Stable Renal Transplant Patients Co-Medicated with Ciclosporin or Sirolimus , 2009, Clinical pharmacokinetics.

[30]  Jerome J. Schentag,et al.  Pharmacodynamics of Vancomycin and Other Antimicrobials in Patients with Staphylococcus aureus Lower Respiratory Tract Infections , 2004, Clinical pharmacokinetics.